Dana-Farber

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana-Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School. Currently, Dana-Farber is ranked the #3 cancer hospital in the world. Two Nobel laureates in Physiology or Medicine are among its past and present faculty. Dana-Farber's research discoveries include the development of the highly successful Gleevec to treat chronic myeloid leukemia.

Read more in the app

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026

Dana-Farber presents Phase 3 lung cancer data in ESMO Presidential Symposium

Dana-Farber breaks ground on Lavine Bekenstein Cancer Hospital

Dana-Farber research reveals possible new target for treatment of sickle cell and beta thalassemia

Dana-Farber’s Edward Chouchani, PhD, selected as a 2026 Blavatnik National Award finalist

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

Dana-Farber investigators develop protein degrader discovery platform and find first-in-kind metabolically activated molecular glue degrader - EurekAlert!

Dana-Farber research supports FDA approval of new therapy for “double-positive” metastatic breast cancer - EurekAlert!

Dana-Farber research supports FDA approval of pembrolizumab-belzutifan combination for higher-risk clear cell kidney cancer after surgery - EurekAlert!

Dana-Farber researchers to present two plenary studies and additional late-breaking cancer research at 2026 ASCO - EurekAlert!

Dana-Farber experts offer perspective on link between pesticide exposure and early-onset colorectal cancer - EurekAlert!

Dana-Farber researchers to present more than 50 research studies at American Association for Cancer Research Annual Meeting 2026 - EurekAlert!

Dana-Farber research helps drive FDA label update for primary CNS lymphoma - EurekAlert!

Breast, lung, and bladder cancer phase 3 trials led by Dana-Farber presented at ESMO Congress 2025 - EurekAlert!

New diagnostic tool developed at Dana-Farber revolutionizes acute leukemia diagnosis - EurekAlert!

For Immediate Release: Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs launch precision genomics initiative for pediatric cancer - EurekAlert!

Global rise in many Early-Onset GI cancers detailed in two Dana-Farber reviews, with colorectal cancer leading the trend - EurekAlert!

FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research - EurekAlert!

Diet influences survival after stage iii colon cancer, Dana-Farber study finds - EurekAlert!